**Invitation for Expression of Interest for providing Clinical Trials Liability Insurance**

ICMR is coordinating the trial, titled “A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications in Moderate Disease”, with at least 25 participating centers.

This phase II, open label, randomized clinical trial was designed with the primary objective to assess the safety and efficacy of the therapy in moderate disease. The Efficacy Objective is: To assess the efficacy of convalescent plasma to limit progression to severe disease in COVID-19 patients. The Safety Objective is: To evaluate the safety of treatment with anti SARS-CoV-2 plasma in patients with COVID-19.

The trial plans to recruit 452 patients, meeting the inclusion and exclusion criteria set for the study, across at least 25 centers across India, and it is expected to be undertaken over 6 months.

Request for proposals are invited from eligible parties who are interested in providing clinical trials liability policy or liability insurance, indicating the conditions and extent of coverage, date of commencement and expiry of coverage, and conditions thereof, including the premium and other costs, as per rules, for the aforementioned studies.

The terms for the policy are –

1. Maximum of 75 Lakh Rupees per occurrence
2. Aggregate insurance of 7.5 Crore Rupees.

Please submit your expression of interest to Email - plasmaconvalescenticmr@gmail.com with complete documentation, by 9pm, 26th April 2020. Please email on the aforementioned email if you need any further documentation.